Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288091 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02288091: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT02288091 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02288091, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a single center, open label, 12-week study of inosine treatment. Inosine treatment leads to an increase in the levels of urate (uric acid) in the blood. The primary objective of the study is to determine the tolerability of oral administration of inosine. Secondary study objectives include the measurement of biomarkers of oxidative stress and damage in response to inosine treatment.
Interventions
- DRUG Inosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02288091
The ClinicalTrials.gov registry entry for NCT02288091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inosine is the first listed.
NCT02288091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02288091 about?
NCT02288091 is a clinical study titled "A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)". This is a single center, open label, 12-week study of inosine treatment. Inosine treatment leads to an increase in the levels of urate (uric acid) in the blood. The primary objective of the study is to determine the tolerability of oral administration of inosine. Secondary study objectives include...
What is the current status of trial NCT02288091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-01. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02288091?
The interventions under investigation include: Inosine (DRUG).
Who is sponsoring clinical trial NCT02288091?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.